You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)
SBC: POLARIS HEALTH DIRECTIONS, INC Topic: NIAAADESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Polaris Oncology Survivor Transition POST System
SBC: POLARIS HEALTH DIRECTIONS, INC Topic: 100DESCRIPTION provided by applicant By January oncology care providers will be expected to craft Survivorship Care Plans SCPs for all individuals ending active treatment for cancer however there is a lack of systematic study of the impact survivorship planning has on patients providers or healthcare systems The Polaris Oncology Survivorship Transition POST program is a web based sy ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Clinical Trial of ABC in Patients with Refractory Multiple Myeloma
SBC: Apogee Biotechnology Corporation Topic: NCIDESCRIPTION provided by applicant Multiple myeloma MM is the second most common hematological malignancy in the United States and remains an incurable disease since nearly all MM patients will eventually relapse and develop resistance to currently available drugs Sphingolipid metabolism is being increasingly recognized as a key pathway in tumor biology In particular sphingosine kinases S ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors
SBC: KEYSTONE NANO, INC. Topic: 102DESCRIPTIONprovided by applicantKeystone Nanoin partnership with the University of Maryland Greenebaum Cancer CenterUMD GCCproposes a multi site clinical evaluation of the Ceramide NanoLiposomeCNLas a novel anti cancer therapeuticThe overall objective of this project is to advance the CNL through a Phase I clinical trialThe results of this trial will support subsequent trials for the intended init ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a MMP Inhibitor for Neuropathic Pain
SBC: AQUILUS PHARMACEUTICALS INC Topic: NIDCRDESCRIPTION provided by applicant Aquilus Pharmaceuticals Inc proposes to preclinically develop AQU for the treatment of orofacial and general neuropathic pain via a newly discovered mechanism involving matrix metalloproteinases andamp MMP MMP AQU is a non hydroxamic acid containing MMP inhibitor that is selective for both MMP and MMP and has been shown to block mech ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
TissueCypher Testing for Risk Assessment in Barretts Esophagus
SBC: Cernostics Inc Topic: 102DESCRIPTION provided by applicant Barrettandapos s esophagus is a pre neoplastic disease that predisposes patients to development of esophageal adenocarcinoma EAC Approximately million people in the US have Barrettandapos s esophagus and they are frequently screened by endoscopy with pathological analyses of esophageal biopsies The goal of the screening is to detect premalignant changes e ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Antibiotics for Recalcitrant Infection
SBC: ARIETIS CORPORATION Topic: RDESCRIPTION provided by applicant The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep seated abscess osteomyelitis endocarditis and biofilms of indwelling devices Many of these infections are essentially untreatable and lead to substantial morbidity and mortality In many cases recalcitrance of an infection is not caused b ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety Risks
SBC: CADUCEUS WIRELESS INC Topic: NDESCRIPTION provided by applicant The overall objective of this Fast Track SBIR application is to create and deploy an innovative system that will help more elders to continue living at home while being safely cared for by Personal Care Service PCS agencies Based on the research teamandapos s prior experience developing fall sensors and other technologies to allow elders to andquot age in pl ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)
SBC: ImCare Biotech LLC Topic: NCIDESCRIPTIONprovided by applicantHepatocellular carcinomaHCCis usually undetected until its later stageswhere theyear survival rate for patients is less thanHoweverthe survival rate can be as high asif the cancer is detected earlyUnfortunatelyearly detection of HCC is not possible with any screening tests that are currently availablesuch as ultrasound or imaging technologiesAlpha FetoproteinAFPwhic ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimization of novel pyranopyridine efflux pump inhibitors
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant Multi drug resistance MDR in Gram negative pathogens including the Enterobacteriaceae and Pseudomonas aeruginosa poses a significant threat to our ability to effectively treat infections caused by these organisms A major component in the development of the MDR phenotype in Gram negative bacteria is overexpression of RND type efflux pumps which actively pu ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health